These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8946661)

  • 1. Interaction of valproic acid with nonsteroidal antiinflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: lack of interaction in uremic sera due to the presence of endogenous factors.
    Dasgupta A; Emerson L
    Ther Drug Monit; 1996 Dec; 18(6):654-9. PubMed ID: 8946661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera. Role of uremic compounds.
    Dasgupta A; Jacques M
    Am J Clin Pathol; 1994 Mar; 101(3):349-53. PubMed ID: 8135194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uremic sera contain inhibitors that block digitoxin-valproic acid interaction.
    Dasgupta A; Paul A; Wells A
    Am J Med Sci; 2001 Oct; 322(4):204-8. PubMed ID: 11678517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Displacement of valproic acid and carbamazepine from protein binding in normal and uremic sera by tolmetin, ibuprofen, and naproxen: presence of inhibitor in uremic serum that blocks valproic acid-naproxen interactions.
    Dasgupta A; Volk A
    Ther Drug Monit; 1996 Jun; 18(3):284-7. PubMed ID: 8738769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valproic acid-ketoconazole interaction in normal, hypoalbuminemic, and uremic sera: lack of interaction in uremic serum caused by the presence of inhibitor.
    Dasgupta A; Luke M
    Ther Drug Monit; 1997 Jun; 19(3):281-5. PubMed ID: 9200768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbamazepine-salicylate interaction in normal and uremic sera: reduced interaction in uremic sera.
    Dasgupta A; Thompson WC
    Ther Drug Monit; 1995 Apr; 17(2):199-202. PubMed ID: 7624911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diminished protein binding capacity of uremic sera for valproate following hemodialysis: role of free fatty acids and uremic compounds.
    Dasgupta A; Jacques M; Malhotra D
    Am J Nephrol; 1996; 16(4):327-33. PubMed ID: 8739287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated free fosphenytoin concentrations in uremic sera: uremic toxins hippuric acid and indoxyl sulfate do not account for the impaired protein binding of fosphenytoin.
    Dasgupta A; Havlik D
    Ther Drug Monit; 1998 Dec; 20(6):658-62. PubMed ID: 9853983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro displacement of phenytoin from protein binding by nonsteroidal antiinflammatory drugs tolmetin, ibuprofen, and naproxen in normal and uremic sera.
    Dasgupta A; Timmerman TG
    Ther Drug Monit; 1996 Feb; 18(1):97-9. PubMed ID: 8848829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.
    Lim CF; Bernard BF; de Jong M; Docter R; Krenning EP; Hennemann G
    J Clin Endocrinol Metab; 1993 Feb; 76(2):318-24. PubMed ID: 8432774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenytoin-oxacillin interactions in normal and uremic sera.
    Dasgupta A; Sperelakis A; Mason A; Dean R
    Pharmacotherapy; 1997; 17(2):375-8. PubMed ID: 9085332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivity of mefenamic acid 1-o-acyl glucuronide with proteins in vitro and ex vivo.
    McGurk KA; Remmel RP; Hosagrahara VP; Tosh D; Burchell B
    Drug Metab Dispos; 1996 Aug; 24(8):842-9. PubMed ID: 8869817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction of protein binding defect in uremic sera by charcoal treatment.
    Craig WA; Evenson MA; Sarver KP; Wagnild JP
    J Lab Clin Med; 1976 Apr; 87(4):637-47. PubMed ID: 1270877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Displacement by anionic drugs of endogenous ligands bound to albumin in uremic serum.
    Mabuchi H; Nakahashi H
    Ther Drug Monit; 1988; 10(3):261-4. PubMed ID: 3140432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin.
    Dasgupta A; Crossey MJ
    Am J Med Sci; 1997 Feb; 313(2):75-9. PubMed ID: 9030671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antioxidant capacity and DNA-interaction studies of zinc complexes with a non-steroidal anti-inflammatory drug, mefenamic acid.
    Tarushi A; Karaflou Z; Kljun J; Turel I; Psomas G; Papadopoulos AN; Kessissoglou DP
    J Inorg Biochem; 2013 Nov; 128():85-96. PubMed ID: 23948577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fast atom bombardment mass spectrometric determination of the molecular weight range of uremic compounds that displace phenytoin from protein binding: absence of midmolecular uremic toxins.
    Dasgupta A; Malik S
    Am J Nephrol; 1994; 14(3):162-8. PubMed ID: 7977474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uricosuric agents in uremic sera. Identification of indoxyl sulfata and hippuric acid.
    Boumendil-Podevin EF; Podevin RA; Richet G
    J Clin Invest; 1975 Jun; 55(6):1142-52. PubMed ID: 1133164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unexpected suppression of free phenytoin concentration by salicylate in uremic sera due to the presence of inhibitors: MALDI mass spectrometric determination of molecular weight range of inhibitors.
    Biddle DA; Wells A; Dasgupta A
    Life Sci; 2000; 66(2):143-51. PubMed ID: 10666010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.
    Miners JO
    Clin Pharmacokinet; 1989 Nov; 17(5):327-44. PubMed ID: 2573442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.